Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review

Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets, and distributes novel innovative branded products. It focuses in the therapeutic areas of women’s health (female sexual dysfunction, hormone replacement therapy) and men’s health (urology). The company’s marketed products include Estrace, for menopausal symptom,s and Natesto, testosterone for male hypogonadism. Acerus pipeline products include Tefina, Avanafil, Elegant and Lidbree indicated for various health issues related to men and women. The company sells products through its salesforce in Canada and licensed distributors in the US and other countries. Acerus is headquartered in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals Corp Key Recent Developments

Dec 26, 2022: Acerus Announces Resignation of Director
Nov 15, 2022: Acerus Reports Third Quarter 2022 Financial Results
Aug 23, 2022: Acerus Announces Resignation of CFO Effective November 20, 2022
Aug 09, 2022: Acerus Reports Second Quarter 2022 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Section 1 - About the Company

Acerus Pharmaceuticals Corp - Key Facts
Acerus Pharmaceuticals Corp - Key Employees
Acerus Pharmaceuticals Corp - Key Employee Biographies
Acerus Pharmaceuticals Corp - Major Products and Services
Acerus Pharmaceuticals Corp - History
Acerus Pharmaceuticals Corp - Company Statement
Acerus Pharmaceuticals Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 - Company Analysis

Company Overview
Acerus Pharmaceuticals Corp - Business Description
R&D Overview
Acerus Pharmaceuticals Corp - Corporate Strategy
Acerus Pharmaceuticals Corp - SWOT Analysis
SWOT Analysis - Overview
Acerus Pharmaceuticals Corp - Strengths
Acerus Pharmaceuticals Corp - Weaknesses
Acerus Pharmaceuticals Corp - Opportunities
Acerus Pharmaceuticals Corp - Threats
Acerus Pharmaceuticals Corp - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Acerus Pharmaceuticals Corp, Recent Deals Summary

Section 5 - Company’s Recent Developments

Dec 26, 2022: Acerus Announces Resignation of Director
Nov 15, 2022: Acerus Reports Third Quarter 2022 Financial Results
Aug 23, 2022: Acerus Announces Resignation of CFO Effective November 20, 2022
Aug 09, 2022: Acerus Reports Second Quarter 2022 Financial Results
Jun 27, 2022: Acerus Announces Voting Results for the 2022 Annual Meeting
May 10, 2022: Acerus Reports First Quarter 2022 Financial Results
May 09, 2022: Acerus Pharmaceuticals Announces annual meeting of the holders
Mar 15, 2022: Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 18, 2022: Acerus announces amendment to loan facilities

Section 6 - Appendix

Methodology
Ratio Definitions
About the Publisher
Contact the Publisher
Disclaimer

List of Tables

Acerus Pharmaceuticals Corp, Key Facts
Acerus Pharmaceuticals Corp, Key Employees
Acerus Pharmaceuticals Corp, Key Employee Biographies
Acerus Pharmaceuticals Corp, Major Products and Services
Acerus Pharmaceuticals Corp, History
Acerus Pharmaceuticals Corp, Subsidiaries
Acerus Pharmaceuticals Corp, Key Competitors
Acerus Pharmaceuticals Corp, Ratios based on current share price
Acerus Pharmaceuticals Corp, Annual Ratios
Acerus Pharmaceuticals Corp, Interim Ratios
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
Acerus Pharmaceuticals Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Acerus Pharmaceuticals Corp, Performance Chart (2017 - 2021)
Acerus Pharmaceuticals Corp, Ratio Charts
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Upsher-Smith Laboratories LLC
Titan Medical Inc
Paladin Labs Inc
Merck Canada Inc
Invaron Pharmaceuticals Inc
Amgen Canada Inc
Allergan Ltd

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€122EUR$125USD£102GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€244EUR$250USD£204GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€366EUR$375USD£306GBP